PathBank

Pathway Description

Etravirine Action Pathway

Homo sapiens

Category:

Metabolite Pathway

Sub-Category:

Drug Action

Created: 2023-03-16

Last Updated: 2023-10-25

Etravirine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV-1 infections in combination with other antiretroviral agents. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Less viral proteins produced, fewer viruses can form.

References

Etravirine Pathway References

De Clercq E: Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. doi: 10.1517/14728214.10.2.241.

Pubmed: 15934866

Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.

Pubmed: 29126136

Highlighted elements will appear in red.

Highlight Compounds

	dATP
	Etravirine

Highlight Proteins

	ABC transporter, substrate-binding lipoprotein
	Reverse transcriptase/RNaseH

Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.

Visualize Compound Data